Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

DR Reddys Laboratories Ltd. RDY

10 fiscal years on record · INR · FY2024 reported · SEC filings only
INR 325.5B
▲ 16.6% YoY
INR 56.5B
▲ 1.5% YoY
INR 18.9B
▼ 34.8% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Dr. Reddy's develops, manufactures and markets generic medicines, with a focus on credible brands, first-to-market launches and differentiated offerings. Its reportable operating segments are Global Generics, Pharmaceutical Services and Active Ingredients, and Others. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products, marketed either under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. Its Pharmaceutical Services and Active Ingredients segment primarily manufactures and markets active pharmaceutical ingredients and intermediates, known as API, which are the principal ingredients for finished pharmaceutical products. It sells its products primarily through clearing and forwarding agents to approximately 6,500 wholesalers who decide which brands to buy based on demand.

Written from the business description in DR. REDDY’S LABORATORIES LIMITED's annual report to the U.S. Securities and Exchange Commission, filed 29 May 2026. Every sentence was checked against that document before publication.

Growth

INR 325.5B
Revenue, FY2024 · full 10-year series below
Revenue INR B Net income INR B
FY2024 · Revenue 325.5 · Net income 56.5
150B300B
2015201820212024
Compound annual growth
+14.9%
+13.3%
+24.8%
+12.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +13.3% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

18 cents
of every revenue dollar became profit
Operating margin Net margin
FY2024 · Operating 22.1% · Net 17.6%
10%20%
201520192024
ROE
FY2024 · ROE 18.4%
10%20%
201520192024
Three returns, three denominators.

Each INR of equity produced 18 cents of profit this year.

Cash & shareholders

INR 8.1B
returned in FY2024 · dividends + net buybacks
Free cash flow INR B
FY2024 · FCF 18.9
20B40B
201520192024
Net buybacks INR B Dividends INR B
FY2024 · Dividends 6.7 · Net buybacks 1.4
10B20BDividendsNet buybacks
2015201620172018201920202021202220232024

INR 6.7B in dividends and INR 1.4B in buybacks — 14% of the year's profit went back to shareholders.

Total assetsINR 493.0B
EquityINR 333.4B
CashINR 14.7B
Gross debtINR 8.7B
Net debtINR -5.9B
Current ratio1.92×

The company holds more cash than debt.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · INR

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
RDY, 10-year financial record
Metric 2024202320222021202020192018201720162015
Revenue INR B325.5279.2245.9214.4189.7174.6153.9142.0140.8154.7
Operating income INR B71.867.757.129.524.316.020.911.913.529.6
EBITDA INR B◌◌◌◌◌◌◌23.624.839.9
Income tax INR B19.516.215.38.79.2−1.53.64.52.67.1
Net income INR B56.555.745.123.617.219.518.89.812.020.0
Free cash flow INR B18.929.047.613.426.025.021.78.79.229.2
EPS, diluted INR 67.7866.8054.17141.69103.65117.40113.0959.0072.09116.98
Dividend / sh INR 40.0040.0030.0025.0025.0020.0020.0020.0020.0020.00
Payout %12121118242021412821
ROE %18.421.821.413.010.513.214.17.89.515.6
Shares out B0.830.170.170.170.170.170.170.170.170.17

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 48 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015. Eight checks were skipped: revenue is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inoutside the United States — SEC code K7
Fiscal year endsMarch 31
Data on record since2015

Share this section

Download image